The Belgian AFMPS warns about risk of hemolysis associated with the use of hydroxychloroquine

Published date20 April 2020
Subject MatterLife Sciences,Prescription Drugs,Drug Distribution,Biopharmaceutical,Research and Development,Belgium,Pharmaceutical Industry,Patient Access,Adverse Impact,Coronavirus/COVID-19
AuthorElisabethann Wright
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT